1. A Review of the Critical Role of Imaging in Primary Liver Malignancy

3. This program may include discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States.

4. Primary Liver Cancer Background

5. Major Risk Factors for HCC

6. Who Should Be Screened for HCC?

7. Screening Recommendations for HCC

8. Screening Case 1 42-Year-Old Man With HBV Infection

9. Screening Case 1 LI-RADS® Classification US-2 Subthreshold

10. Screening Case 2 39-Year-Old Man With Alcohol-Related Cirrhosis

11. Screening Case 2 Findings US-1 Negative With Severe Limitations

12. Diagnostic Imaging in HCC

13. Use of Contrast in Liver MRI

14. Diagnostic Case 1: 70-Year-Old Man With HCV-Related Cirrhosis and Positive HCC Screening

15. LI-RADS® Classification Overview

16. LI-RADS® Classification Overview

17. LI-RADS® Classification Overview

18. Diagnostic Case 2: 59-Year-Old Man With Cirrhosis Caused by HBV and HCV Infection

19. Diagnostic Case 2 LI-RADS® Classification

20. Diagnostic Case 2 LI-RADS® Classification

21. Diagnostic Case 2 LI-RADS® Classification

22. Diagnostic Case 2 LI-RADS® Classification

23. TNM Staging for HCC

24. Imaging Treatment Response in HCC

25. LI-RADS® Guidance on Assessing Treatment Response in HCC

26. Treatment Response Categories

27. Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US

28. Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US (cont)

29. Treatment Response Case 1: 65-Year-Old Woman With HCV-Related Cirrhosis With Positive US (cont)

30. Embolic Treatment Response

31. Measurement of Viable Tumor

32. LI-RADS® Technical Recommendations for MRI

33. LI-RADS® Technical Recommendations for CT

34. CEUS

35. CEUS (cont)

36. Concluding Remarks

37. Abbreviations